title: Clinical pharmacology of 9-aminocamptothecin.
authors.affiliation: NCI-Navy Medical Oncology Branch, Bethesda Naval Hospital, Maryland 20889, USA.
authors.forename: C H
authors.initials: CH
authors.lastname: Takimoto
authors.forename: W
authors.initials: W
authors.lastname: Dahut
authors.forename: N
authors.initials: N
authors.lastname: Harold
authors.forename: H
authors.initials: H
authors.lastname: Nakashima
authors.forename: R
authors.initials: R
authors.lastname: Lieberman
authors.forename: M D
authors.initials: MD
authors.lastname: Liang
authors.forename: S G
authors.initials: SG
authors.lastname: Arbuck
authors.forename: A P
authors.initials: AP
authors.lastname: Chen
authors.forename: J M
authors.initials: JM
authors.lastname: Hamilton
authors.forename: L R
authors.initials: LR
authors.lastname: Cantilena
authors.forename: C J
authors.initials: CJ
authors.lastname: Allegra
authors.forename: J L
authors.initials: JL
authors.lastname: Grem
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D059004:Topoisomerase I Inhibitors
chemical_list: D000970:Antineoplastic Agents; D059004:Topoisomerase I Inhibitors; C080125:9-aminocamptothecin; D002166:Camptothecin